Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients

Table 3 Characteristics and outcomes of recipients with post-transplant tertiary hyperparathyroidism stratified by treatment modalities, n (%)

Variables	Conservative management (n = 40)	Calcimimetics (n = 42)	parathyroidectomy (n = 41)	Total (n = 123)	P value
Age (years), mean (SD)	52.1 (14.2)	50.4 (11.6)	49.6 (12.8)	50.7 (12.8)	0.679
Duration of pre-transplant renal replacement therapy (months), median (IQR)	24.0 (6.0-54.0)	48.5 (24.0-66.0)	24.0 (1.5-50.0)	31.0 (7.0-57.0)	0.049
Baseline eGFR (mL/minute/1.73 m2), median (IQR)	50.4 (37.0-59.2)	53.5 (43.0-71.8)	48.0 (38.0-59.0)	50.8 (39.0-62.5)	0.174
Median pre-transplant calcium (mmol/L), median (IQR)	2.5 (2.4-2.5)	2.4 (2.3-2.5)	2.5 (2.4-2.6)	2.5 (2.4-2.6)	0.184
Median pre-transplant phosphate (mmol/L), median (IQR)	1.6 (1.4-1.9)	1.7 (1.4-2.0)	1.6 (1.4-1.8)	1.6 (1.4-1.9)	0.621
Median pre-transplant parathyroid hormone (pmol/L), median (IQR)	295.0 (138-478)	643.5 (340-1163)	374 (190-599)	374 (216-719)	< 0.001
The eGFR slope (mL/minute/year), median (IQR)	-1.02 (-1.94 to 0.38)	-1.78 (-3.80 to 0.01)	-1.09 (-3.21 to -0.18)	-1.27 (-3.67 to -0.09)	0.378
History of acute rejection	4 (10.5)	5 (12.5)	10 (24.4)	19 (16.0)	0.186

eGFR: Estimated glomerular filtration rate; IQR: Interquartile range.